5.09
-0.105(-2.02%)
Currency In USD
| Previous Close | 5.19 |
| Open | 5.19 |
| Day High | 5.19 |
| Day Low | 5.01 |
| 52-Week High | 10.28 |
| 52-Week Low | 3.81 |
| Volume | 12,116 |
| Average Volume | 125,045 |
| Market Cap | 52.12M |
| PE | -5.53 |
| EPS | -0.92 |
| Moving Average 50 Days | 5.38 |
| Moving Average 200 Days | 5.26 |
| Change | -0.11 |
If you invested $1000 in Serina Therapeutics Inc (SER) since IPO date, it would be worth $52.54 as of September 16, 2025 at a share price of $5.085. Whereas If you bought $1000 worth of Serina Therapeutics Inc (SER) shares 5 years ago, it would be worth $161.43 as of September 16, 2025 at a share price of $5.085.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
GlobeNewswire Inc.
Sep 09, 2025 7:20 PM GMT
Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutive alternati
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 08, 2025 10:00 AM GMT
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger,
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
GlobeNewswire Inc.
Aug 25, 2025 8:15 PM GMT
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE Americ